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Abstract The aim of this clinical trial was to evaluate the
impact of all-trans retinoic acid (ATRA) in combination with
chemotherapy and to assess the NPM1 status as biomarker for
ATRA therapy in younger adult patients (18–60 years) with
acute myeloid leukemia (AML). Patients were randomized for
intensive chemotherapy with or without open-label ATRA
(45 mg/m2, days 6–8; 15 mg/m2, days 9–21). Two cycles of
induction therapy were followed by risk-adapted consolida-
tion with high-dose cytarabine or allogeneic hematopoietic
cell transplantation. Due to the open label character of the
study, analysis was performed on an intention-to-treat (ITT)
and a per-protocol (PP) basis. One thousand one hundred
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patients were randomized (556, STANDARD; 544, ATRA)
with 38 patients treated vice versa. Median follow-up for
survival was 5.2 years. ITT analyses revealed no difference
between ATRA and STANDARD for the total cohort and for
the subset of NPM1-mutated AML with respect to event-free
(EFS; p = 0.93, p = 0.17) and overall survival (OS; p = 0.24
and p = 0.32, respectively). Pre-specified PP analyses revealed
better EFS inNPM1-mutatedAML (p = 0.05) and better OS in
the total cohort (p = 0.03). Explorative subgroup analyses on
an ITT basis revealed better OS (p = 0.05) in ATRA for
genetic low-risk patients according to ELN recommendations.
The clinical trial is registered at clinicaltrialsregister.eu
(EudraCT Number: 2004-004321-95).
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Introduction
All-trans retinoic acid (ATRA) in combination with chemo-
therapy or arsenic trioxide (ATO) has revolutionized the treat-
ment of acute promyelocytic leukemia (APL) [1, 2]. However,
early preclinical studies also provided a rationale for the use of
ATRA in non-APL acute myeloid leukemia (AML) [3–9].
In vitro studies showed efficacy of ATRA in non-APL AML
cell lines and primary AML blasts, especially in co-treatment
of leukemic blasts with cytarabine [3–5] or idarubicin [6].
These in vitro experiments provided important evidence
that the addition of ATRA to cytarabine or idarubicin only
increases the killing of clonogenic cells when ATRA is
administered after exposure to the cytotoxic drug [3–7].
Besides a shortening of the BCL2 half-life, which has been
implicated as a resistance mechanism in AML [3, 5, 8, 10], an
additional potential pathophysiological mechanism of the anti-
leukemic activity of ATRA was described by Balusu et al. in
AML with mutant NPM1 [11]. NPM1 levels attenuated by
ATRA selectively induced apoptosis and sensitized AML with
mutant NPM1 to treatment with ATRA and cytarabine [11].
More recently, two groups showed that the combination of
ATRA and ATO synergistically induced proteasomal degrada-
tion of mutant NPM1, leading to growth arrest, differentiation
and apoptosis [12, 13].
Based on the promising in vitro data, several clinical trials
evaluated ATRA in combination with chemotherapy in non-
APL AML. Encouraging data from a phase II trial combining
low-dose cytarabine with ATRA in 33 patients ineligible for
intensive therapy [14] triggered larger up-front randomized
trials [15–19]. The results from these randomized studies have
been contradictory, with the majority reporting negative
results. In the study by Estey et al. of 215 patients with high-
risk myelodysplastic syndrome or AML older than 71 years,
there was no effect of ATRA in multivariable analysis, but a
significantly better overall survival was found in univariable
analyses for patients treated in the ATRA arms [15]. The
British Medical Research Council (MRC) performed three
randomized trials, one in younger patients receiving intensive
first-line treatment (MRC AML12, n = 1097) [16], one in
medically unfit patients (MRC AML14, n = 207) [17], and
one in high-risk refractory or relapsed patients (MRC
AML-HR, n = 362) [18], without showing a significant effect
of ATRA on any endpoint analyzed.
In these trials showing negative results, ATRA consistently
was started simultaneously [16–18] or before initiation of che-
motherapy [15]. In contrast, in our AMLHD98B trial of 242
older patients, ATRAwas started at the end of chemotherapy
in accordance with the in vitro data [3–7, 19]. In this trial,
patients randomized to the ATRA arm had a significantly
higher complete remission (CR) rate, better event-free and
overall survival [19]. In a subsequent subgroup analysis of
the up-front randomized patients (206 of 242), the genotype
mutated NPM1 in the absence of FLT3 internal tandem dupli-
cation (ITD) emerged as a predictive marker for the beneficial
effect of ATRA [20]. However, similar biomarker analyses on
selected patients (592 of 1075) of the MRC AML 12 trial
again did not reveal a beneficial clinical effect of ATRA in
any of the analyzed subgroups [21]. Although not statistically
significant but consistent with the results of the AMLHD98B
trial, a better relapse-free and overall survival was present in
patients exhibiting the genotypemutatedNPM1 in the absence
of FLT3-ITD who had been randomized to the ATRA arm
(estimated hazard ratio for overall survival, 0.70; 95 %
confidence interval [CI], 0.42–1.16) [21].
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In 2004, we initiated the up-front randomizedAMLSG07-04
four-arm study evaluating in a two-by-two factorial design
ATRA and valproic acid (VPA) as adjunct to intensive induction
and consolidation therapy. In 2006, the protocol was amended
and the randomization for VPAwas terminated based on exces-
sive hematologic toxicity of VPA in combination with chemo-
therapy, which was similarly noted in older patients [22]. Here,
we report the results of the upfront randomization for ATRA in
1100 younger adult patients.
Patients and methods
Patients
Patients aged between 18 and 60 years with newly diagnosed
AML including de novo AML, secondary AML with a
preceding history of myelodysplastic or myeloproliferative
disorder (sAML) and therapy-related AML following treat-
ment of a primary malignancy (tAML), as defined by the
WHO 2001 classification were eligible for the trial [23].
Patients with acute promyelocytic leukemia (APL) as well as
patients with concomitant renal (creatinine > 1.5 x upper nor-
mal serum level), liver (bilirubin, AST or AP > 2 x upper nor-
mal serum level) or cardiac dysfunction (New York Heart
Association III/IV), uncontrolled infectious disease, primary
coagulation disturbance or performance status (ECOG) >2
were excluded. Written informed consent was obtained from
all patients. The protocol was approved by the lead Ethics
Review Committee and registered at clinicaltrialsregister.eu
(EudraCT Number: 2004-004321-95) and clinicaltrials.gov
(NCT00151242).
Cyto- and molecular genetics
Chromosome banding analysis was performed centrally in the
two AMLSG Laboratories for Cytogenetics (Hannover, Ulm).
Karyotypes were designated according to the International
System for Human Cytogenetic Nomenclature [24].
Leukemia samples were analyzed for mutations in FLT3
(ITDs and tyrosine kinase domain [TKD] mutations at codons
D835/I836), NPM1, CEBPA, DNMT3A, RUNX1, IDH1/2,
ASXL1 and CEBPA as previously described [20, 25–29].
Study design
Induction therapy
From August 2004 to January 2006, patients were randomized
in a two-by-two factorial design to receive induction chemother-
apy with or without ATRA andwith or without VPA resulting in
four arms, ATRA, ATRA-VPA, VPA and STANDARD. In
January 2006, randomization for VPA was terminated due to
increased hematologic toxicity whereas randomization for
ATRA was carried forward. Induction therapy consisted of 2
cycles ICE (idarubicin, 12mg/m2 i.v., days 1, 3 and 5; cytarabine,
100 mg/m2 cont. i.v., days 1–7; etoposide 100 mg/m2 i.v., days
1–3) or the same chemotherapy plus ATRA (ATRA p.o.,
45 mg/m2, days 6–8 and 15 mg/m2, days 9–21). Patients
achieving a CR or partial remission (PR) after the first induction
received a second cycle according to their initial randomization
with a reduced dosage of idarubicin (12 mg/m2, days 1 and 3).
Consolidation therapy
Patients with high-risk AML defined either by high-risk cyto-
genetics or induction failure [30] were assigned to receive an
allogeneic hematopoietic cell transplantation (HCT) from a
matched related (MRD) or unrelated donor (MUD). Starting
from December 2006, AML exhibiting a FLT3-ITD was also
categorized as high risk [25]. All other patients were assigned
either to three cycles of high-dose cytarabine (HiDAC) from
August 2004 to November 2006 with cytarabine 3 g/m2 bid,
days 1, 3 and 5, and from November 2006 with a condensed
schedule with application of cytarabine 3 g/m2 bid, days 1, 2
and 3. If an MRD was available, an allogeneic HCT was
intended in first CR in all patients except those with core-
binding factor AML.
Definition of response criteria, survival endpoints
and hematologic recovery
In accordancewith standard criteria, CRwas defined as less than
5% bonemarrow blasts, an absolute neutrophil count of 1.0G/L
or higher, a platelet count of 100 G/L or higher, no blasts in the
peripheral blood and no extramedullary leukemia; CR with in-
complete blood count recovery (CRi) was characterized as CR
except for residual neutropenia (neutrophils <1.0 G/L) or throm-
bocytopenia (platelets <100 G/L) [31]. Relapse was defined as
more than 5 % bone marrow blasts unrelated to recovery from
the preceding course of chemotherapy or new extramedullary
leukemia in patients with previously documented CR.
Event-free survival (EFS), relapse-free survival (RFS) and
overall survival (OS) were defined as recommended [31].
Times to leukocyte, neutrophil and platelet recovery were mea-
sured from the first day of chemotherapy of each cycle until the
first day with values more than or equal to 1, 0.5 and 20 G/L for
white blood cells (WBC), neutrophils and platelets, respectively.
Toxicities were defined and graded according to the National
Cancer Institute (NCI) Common Toxicity Criteria, version 2.0.
Statistical analysis
Pairwise comparisons between patient subgroups were per-
formed by the Mann-Whitney or Kruskal-Wallis test for con-
tinuous variables and by Fisher’s exact test for categorical
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variables. Univariable and multivariable logistic regression
models were applied to investigate the influence of covariates
on response to induction therapy.
The analysis were performed on an intention-to-treat (ITT)
according to initial randomization result and a per protocol
(PP) basis according to received treatment. The primary end-
point of the study was EFS; secondary endpoints were OS,
RFS, therapy-related toxicity and their correlation with the
study drug. The median duration of follow-up was calculated
by the reverse Kaplan-Meier estimate [32]; the Kaplan-Meier
method was used to estimate the distributions of EFS, RFS
and OS. Survival distributions were compared using the log-
rank test. Multivariable Andersen-Gill regressionmodels were
used to evaluate prognostic variables including allogeneic
HCT as a time-dependent covariable [33]. In addition, the
following variables were evaluated in multivariable regression
models: WBC (median-dichotomized), age, gender, genetic-
risk group according to European LeukemiaNet (ELN) rec-
ommendations (favorable, intermediate-1, intermediate-2, ad-
verse) [34], type of AML (de novo, sAML/tAML), randomi-
zation (STANDARD, ATRA), FLT3-TKD, FLT3-ITD,
NPM1, biallelic mutated CEBPA, DNMT3A; IDH1, IDH2,
RUNX1 and ASXL1 mutational status and VPA (received,
not received). Pre-specified subset analyses, according to the
NPM1 and the combined NPM1 and FLT3-ITD mutational
status, were performed for all endpoints. Missing data were
replaced by 50 imputations using multivariate imputations by
chained equations applying predictive mean matching [35].
Backward selection applying a stopping rule based on a
p value of 0.50 was used in multivariable regression models to
exclude redundant or unnecessary variables [35].
All statistical analyses were performed with the statistical
software environment R, version 3.0.1, using the R packages
rms, version 3.6-3, and cmprsk, version 2.2-2 [36].
Results
Patients and baseline characteristics
A total of 1229 patients were registered, 809 were randomized
first within the framework of the cooperative German AML
Intergroup Study [37] in a ratio 1:10 into a common standard
arm (n = 85) or the study group specific protocol (n = 724),
and thereafter, 420 patients were directly registered for the
AMLSG 07-04 protocol. Of 1144 randomized patients, 44
were excluded due to violation of in-/exclusion criteria (n =
29), no informed consent (n = 10) or other reasons (n = 5).
Between August 2004 and January 2006, patients were
assigned to one of four arms according to the two-by-two
factorial design, ATRA (n = 97), ATRA-VPA (n = 91), VPA
(n = 95) and STANDARD (n = 98). After termination of the
VPA-randomization, additional n = 719 patients were
randomized for ATRA resulting in 544 patients in the ATRA
(ATRA) and 556 in the STANDARD arm of the study
(Table 1). Table 1 shows patient demographics and presenting
laboratory and genetic characteristics by up-front randomiza-
tion for ATRA. Patients in ATRA were characterized by
significantly lower WBC (p = 0.003) and peripheral blast per-
centage (p = 0.003) compared to patients in STANDARD.
Nine randomized patients did not receive the scheduled ther-
apy, due to death before start of induction therapy (ATRA,
n = 4; ATRA-VPA, n = 2; VPA, n = 0; STANDARD, n = 3).
In spite of the initial randomization to ATRA, 19 patients
did not receive ATRA due to the local physicians’ judgment.
On the other hand, 19 patients received ATRA although
randomized to STANDARD. According to the protocol and
the open-label character of the study, ITT analyses followed
by PP analyses were performed.
The trial flow is summarized in the diagram according to
CONSORT statement in Fig. 1.
Response to induction therapy
After the first induction cycle, there was no significant difference
between the two treatment arms on an ITT basis (ATRA, 50.9%;
STANDARD, 48.7 %) in achieving of CR/CRi (p = 0.47). In
contrast, the PP analysis revealed a significantly (p = 0.03) higher
CR/CRi rate in the ATRA (53.1 %) compared to the
STANDARD arm (46.6 %). After double induction therapy,
ITT analyses did not reveal a significant difference in CR/CRi
rate (p = 0.95) between ATRA (73.3 %) and STANDARD
(73.6 %), whereas in the PP analyses the CR/CRi rate in patients
receiving ATRA (75.9 %) was in trend superior (p= 0.08) com-
pared to patients in STANDARD (71.0 %). In the predefined
NPM1-subsets (accounted for FLT3-ITD), no significant differ-
ence were identified.
Multivariable logistic regression analysis in all patients
revealed no impact of ATRA on an ITT and PP basis
(Supplementary Table 1).
In patients receiving ATRA, a low (2 %) but significantly
(p = 0.04) increased rate of allergic reactions grade III/IV was
reported compared to STANDARD (1 %). Of note, in
STANDARD cardiac grade III/IV events were significantly
(p = 0.03) more frequent (4 %) compared to ATRA (1.5 %).
All other reported toxicities were equally distributed
(Supplementary Table 2). No difference (p = 0.80) in death rate
during double induction therapy was present between ATRA
(5.7 %) and STANDARD (6.1 %). Recovery times of neutro-
phils (p = 0.61) and platelets (p = 0.70) after the first induction
cycle were comparable between STANDARD and ATRA.
Consolidation therapy
Allogeneic HCT in first CR after first or second induction
therapy was performed in 57 and 62 patients in STANDARD
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Table 1 Description of patient
characteristics, clinical and
laboratory
Standard ATRA p value
n = 556 n = 544
No. (%) No. (%)
Age [years], median (range) 48.8 (18–61) 48.5 (18–61) 0.56
Gender [male], No. (%) 283 (50.9) 288 (52.9) 0.51
WBC [109/l], median (range) 16.0 (0.3–532) 9.2 (0.3–349) 0.003
Missing 3 8
Platelets [109/l], median (range) 52 (3–590) 58 (4–933) 0.11
Missing 4 8
Hemoglobin [g/dL], (median, range) 9.1 (3.8–15.3) 9.2 (3.5–16.0) 0.77
Missings 3 7
LDH [U/l], median (range) 445 (94–15098) 407.5 (84–6907) 0.18
Missings 8 8
BM-blasts [%], median (range)* 75 (0–100) 70 (2–100) 0.14
Missings 30 33
PB-blasts [%], median (range) 36 (0–100) 27 (0–100) 0.003
Missings 39 36
Type of AML, No. (%) 0.99
De novo 484 (87) 473 (87)
sAML 31 (5.6) 30 (5.5)
tAML 40 (7.2) 40(7.4)
Cytogenetic risk, No. (%) 0.58
CBF-AML 65 (12.8) 56 (11.0)
Intermediate 336 (66.1) 338 (66.1)
Adverse30 107 (21.1) 117 (22.9)
Normal karyotype, No. (%) 246 (48.4) 248 (48.5) 0.99
Missings 48 33
Biallelic mutated CEBPA, No. (%) 26 (5.3) 23 (4.8) 0.77
Missings 61 64
FLT3-ITD, No. (%) 107 (20.2) 102 (20.1) 0.99
Missings 26 36
FLT3-TKD, No. (%) 28 (5.3) 25 (5.0) 0.89
Missings 29 40
Mutated NPM1, No. (%) 149 (29.2) 138 (27.8) 0.68
Missings 46 47
Mutated DNMT3A, No. (%) 109 (21.5) 119 (23.9) 0.37
Missings 48 47
Mutated IDH1, No. (%) 26 (6.1) 29 (6.8) 0.68
Missings 127 120
Mutated IDH2R140, No. (%) 30 (7.0) 29 (6.9) 0.99
Mutated IDH2R172, No. (%) 12 (2.8) 11 (2.6)
Missings 130 122
Mutated RUNX1, No. (%) 39 (9.4) 32 (7.9) 0.54
Missings 139 140
Mutated ASXL1, No. (%) 22 (5.3) 21 (5.1) 0.99
Missings 141 131
ELN genetic risk group 0.80
Favorable risk, No. (%) 152 (30.3) 139 (28.0)
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and ATRA, respectively; in addition, 50 and 52 patients in
STANDARD and ATRA with RD after induction therapy
received allogeneic HCT in first CR following successful
salvage therapy outside the protocol (Fig. 1).
One consolidation therapy with high-dose cytarabine
was admin i s t e r ed i n 272 and 256 pa t i e n t s i n
STANDARD and ATRA, respectively; all three cycles of
high-dose cytarabine were administered in 192 and 167
patients in STANDARD and ATRA, respectively. During
consolidation therapy, 48 and 53 patients proceeded to al-
logeneic HCT in first CR in STANDARD and ATRA, re-
spectively. In total, 155 and 167 patients received alloge-
neic HCT in first CR in STANDARD and ATRA, respec-
tively. In addition, 149 patients received allogeneic HCT
with active disease (STANDARD, n = 73; ATRA, n = 76)
during first line therapy.
Survival analyses
Estimated median follow-up for survival was 5.23 years
(95 % CI, 5.02–5.37) without difference according the
treatment arms (p = 0.69). Of the 1100 randomized pa-
tients, 808 achieved a first CR; of these, 397 relapsed,
and overall, 562 died. After relapse, 88 and 90 % of the
patients in STANDARD and ATRA were treated inten-
sively (p = 0.43). Allogeneic HCT after relapse was per-
formed in 231 patients (ATRA, n = 107; STANDARD,
n = 124).
Univariable survival analyses on an ITT basis revealed
no significant differences for EFS (p = 0.93), RFS (p =
0.25) and OS (p = 0.24, Fig. 2) according to the treatment
arm. However, PP analyses showed a trend for superior
EFS (p = 0.09) and a statistically significant better OS
(p = 0.03, Fig. 2) for patients in ATRA compared to
STANDARD, but no difference in RFS (p = 0.14). In the
pre-defined predictive marker study, ITT analyses
(Supplementary Figure 1) revealed no significant impact of
ATRA in the NPM1-mutated and NPM1-wildtype subgroups
for EFS (p = 0.17, p = 0.48) for RFS (p = 0.38, p = 0.28) and OS
(p = 0.44 and p = 0.70, respectively), whereas PP analyses
revealed significantly improved EFS for ATRA in the NPM1-
mutated subgroup (p = 0.05, Supplementary Figure 2).
Explorative analyses in molecularly defined subsets on OS re-
vealed a significant beneficial effect on an ITT (Table 2) and PP
basis (Supplementary Figure 3) of ATRA in patients in the ELN
favorable-risk category (p= 0.05 and p = 0.05, respectively), and
in particular, those patients exhibiting biallelicCEBPAmutations
(p = 0.04 and p = 0.03, respectively).
Multivariable analyses for EFS and OS including allogeneic
HCT in first CR as time-dependent variable revealed no signif-
icant impact of ATRA on an ITT basis. However, on a PP basis,
ATRAwas associated with a significantly (HR, 0.82; p = 0.02)
better OS (Tables 3, 4, 5, and 6).
Overall, 473 patients relapsed after achieving a first
remission either on the protocol (n = 397) or after salvage
therapy (n = 76). According to ELN-risk groups, 130 pa-
tients had a favorable risk (CBF-AML, biallelic mutated
CEBPA, mutant NPM1/FLT3-ITDneg) and 263 patients
had no favorable risk. Of the relapsed patients with favor-
able risk, 95 patients received allogeneic HCT after re-
lapse; of the 6 patients who had been transplanted in the
first CR, 4 patients received a second allogeneic HCT and
2 patients received autologous HCT; and 27 patients were
treated with chemotherapy only. Relapsed patients within
all other ELN risk groups were treated after relapse with
allogeneic HCT (n = 116) or chemotherapy (n = 78); of 78
patients who had been transplanted in first CR, 24 patients
received second allogeneic HCT and 54 patients chemothera-
py only. The second CR rates, also including CRs achieved
after allogeneic HCT, were not significantly different in
Table 1 (continued)
Standard ATRA p value
n = 556 n = 544
No. (%) No. (%)
Intermediate-2 risk, No. (%) 153 (30.5) 151 (30.4)
Intermediate-2 risk, No. (%) 90 (17.9) 90 (18.1)
Adverse risk, No. (%) 107 (21.3) 117 (23.5)
Missings 54 47
Abbreviations: WBC white blood count, LDH lactate-dehydrogenase, BM bone marrow, PB peripheral blood,
sAML secondary AML after a preceding MDS; tAML treatment-related AML, CBF- AML core-binding factor
AML, CEBPA CCAAT/enhancer binding protein alpha, FLT3-ITD FMS-like tyrosine kinase 3 gene internal
tandem duplication, FLT3-TKD FMS-like tyrosine kinase 3 gene tyrosine kinase domain mutation, NPM1
nucleophosmin, DNMT3A DNA (cytosine-5-)-methyltransferase 3 alpha, IDH Isocitrate dehydrogenase,
RUNX1 Runt-related transcription factor 1, ASXL1 additional sex combs like 1, transcriptional regulator
*In case of BM blasts <20 %, diagnosis of AML was established based on extramedullary disease or
PB blast >20 %
1936 Ann Hematol (2016) 95:1931–1942
STANDARD and ATRAwith 65 % (45/69) and 73 % (45/61)
in the favorable-risk group, and 48 % (67/141) and 54 % (66/
122) in other ELN-risk groups, respectively. In contrast, treat-
ment with ATRA during first-line therapy had a major impact
on OS after relapse. Patients in the favorable-risk group had a
significantly superior OS after relapse if they had received
ATRA (ITT, p = 0.006; PP, p = 0.02; Fig. 3a) during the first-
line therapy, whereas this was not the case in the other ELN-risk
groups (ITT, p = 0.98; PP, p = 0.71; Fig. 3b).
Discussion
We previously reported that ATRA given in combination with
intensive chemotherapy improves survival in older patients with
AML [19]. The objectives of this trial were to perform a confir-
matory study in a younger patient population and to endorse
mutant NPM1 as a predictive factor for response to ATRA [20].
Induction therapy consisted of idarubicin, etoposide and
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Fig. 1 Flow chart on study conduct. Flow chart showing enrollment, program completion and/or drop-out according to the randomization result.
Abbreviations: IC informed consent, RD refractory disease, HCT hematopoietic cell transplantation
preclinical data, we decided to start ATRA at day 6, that is, after
most of the cytotoxic drugs were administered; furthermore, we
reduced the daily dose to 15 mg/m2 at day 9 to avoid undue
toxicity. Due to the open-label character of the study, we im-
plemented in the protocol predefined ITT as well as PP analy-
ses. Our results show that the addition of ATRA to intensive
induction therapy is feasible with three days of 45 mg/m2
followed by a dose reduction to 15 mg/m2 and not associated
with relevant additional toxicity. This is in contrast to the results
reported in the NCRI AML16 trial, in which continuous high
doses of ATRA (45 mg/m2) have led to excessive toxicity in
616 randomized patients with a significant increase in the
30-day mortality rate of 20 % in the ATRA arm as com-
pared to 12 % in the standard arm (p = 0.005) [38].
Overall, we were not able to show a significant beneficial
effect of ATRA on an IIT basis on the primary endpoint EFS
and the secondary endpoints CR rate, RFS and OS. In addi-
tion, we were also not able to confirm, on an ITT basis, the
predictive value of NPM1 mutational status on the beneficial
effect of ATRA on clinical endpoints. Thus, our data confirm
the results fromMRC showing no impact of ATRA on clinical

































Fig. 2 Survival analyses
according to randomization
according to intention-to-treat and
per-protocol analysis
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Table 2 Stratified analyses of ATRA on an intention-to-treat basis by genetic risk group according to ELN recommendations and mutational status of
NPM1, FLT3-ITD, DNMT3A, IDH1/2, CEBPA and RUNX1 on overall survival
*Log-likelihood ratio test
mutated NPM1 with or without FLT3-ITD [21]. However, PP
analyses revealed some efficacy of ATRA in the total cohort
for OS (p = 0.03) and for EFS in NPM1-mutated AML (p =
0.05). Although PP analyses may be biased, these results are
supported by multivariable models accounting for important
base-line variables and allogeneic HCTwhich was included as
a time-dependent covariable. Thus, to some extent, our previ-
ous data on the beneficial clinical effect of ATRA overall [19]
as well as in a genetically defined subgroup [20] were support-
ed by the results of the current study.
Our clinical results are supported by recent in vitro data in
cell lines and primary AML blasts showing the ability of
ATRA to induce a significant amount of apoptosis in some
(3 out of 11) primary leukemia samples from patients with
NPM1 mutation which was potentiated by combination with
ATO [13]. In addition, ATRA alone was also able to induce a
Table 6 Andersen-Gill regression model with the endpoint OS
analysed on a per-protocol basis
HR 95 % CI p value
Genetic risk according to ELN
Favorable risk 0.45 0.34–0.58 <0.0001
Intermediate-2 1.03 0.80–1.33 0.81
Adverse risk 1.88 1.51–2.34 <0.0001
s/t-AML 1.33 1.05–1.68 0.019
Gender (male) 1.22 1.03–1.44 0.019
Age (diff. 10 years) 1.24 1.14–1.34 <0.0001
WBC (median-dichotomized)* 1.51 1.26–1.81 <0.0001
Valproic acid 1.35 1.10–1.67 0.005
Allogeneic HCT in 1st CR 0.71 0.58–0.88 0.001
ATRA 0.81 0.69–0.96 0.017
Variables excluded after limited backward selection in the order of their
exclusion: DNMT3A mutational status (p = 0.87), ASXL1 mutational sta-
tus (p = 0.70), RUNX1 mutational status (p = 0.61), FlT3-tKd (p = 0.53),
IDH2mutational status (p = 0.35), IDH1mutational status (p = 0.34) and
age (p = 0.08)
*The median WBC of the whole cohort was 12.7 G/L reference group
intermediate-1
Table 5 Andersen-Gill regression model with the endpoint OS
analysed on an intention-to-treat basis
HR 95 % CI p value
Genetic risk according to ELN
Favorable risk 0.45 0.34–0.58 <0.0001
Intermediate-2 1.03 0.80–1.32 0.84
Adverse risk 1.87 1.50–2.34 <0.0001
s/t-AML 1.32 1.04–1.67 0.021
Gender (male) 1.22 1.03–1.44 0.024
Age (diff. 10 years) 1.23 1.13–1.34 <0.0001
WBC (median-dichotomized)* 1.55 1.30–1.85 <0.0001
Valproic acid 1.36 1.10–1.67 0.004
Allogeneic HCT in 1st CR 0.71 0.58–0.87 0.001
ATRA 0.89 0.76–1.06 0.19
Variables excluded after limited backward selection in the order of their
exclusion: DNMT3A mutational status (p = 0.95), FLT3-TKD (p = 0.85),
ASXL1 mutational status (p = 0.70), RUNX1 mutational status (p = 0.52),
IDH1 mutational status (p = 0.29) and IDH2 mutational status (p = 0.13)
*The median WBC of the whole cohort was 12.7 G/L reference group
intermediate-1
Table 3 Andersen-Gill regression model with the endpoint EFS
analysed on an intention-to-treat basis
HR 95 % CI p value
Genetic risk according to ELN
Favorable risk’ 0.38 0.31–0.47 <0.0001
Intermediate-2’ 1.05 0.86–1.30 0.62
Adverse-risk’ 1.80 1.48–2.18 <0.0001
s/t-AML 1.28 1.04–1.57 0.020
Gender (male) 1.35 1.17–1.56 <0.0001
WBC (Median-dichotomized)* 1.29 1.11–1.49 0.001
Valproic acid 1.22 1.02–1.47 0.032
Allogeneic HCT in 1st CR 0.47 0.38–0.60 <0.0001
ATRA 0.99 0.86–1.14 0.87
Variables excluded after limited backward selection in the order of their
exclusion: DNMT3A mutational status (p = 0.82), ASXL1 mutational sta-
tus (p = 0.70), RUNX1 mutational status (p = 0.56), FLT3-TKD (p =
0.48), IDH2 mutational status (p = 0.39), IDH1 mutational status (p =
0.32) and age (p = 0.10)
*The median WBC of the whole cohort was 12.7 G/L
Table 4 Andersen-Gill regression model with the endpoint EFS
analysed on a per-protocol basis
HR 95 % CI p value
Genetic risk according to ELN
Favorable risk 0.38 0.31–0.47 <0.0001
Intermediate-2’ 1.05 0.86–1.29 0.63
Adverse risk 1.79 1.48–2.17 <0.0001
s/t-AML 1.28 1.04–1.58 0.018
Gender (male) 1.35 1.17–1.56 <0.0001
WBC (median-dichotomized)* 1.27 1.10–1.47 0.001
Valproic acid 1.22 1.02–1.47 0.032
Allogeneic HCT in 1st CR 0.47 0.37–0.59 <0.0001
ATRA 0.88 0.76–1.01 0.07
Variables excluded after limited backward selection in the order of their
exclusion: DNMT3A mutational status (p= 0.87), ASXL1 mutational
status (p = 0.72), RUNX1 mutational status (p = 0.61), FLT3-TKD
(p = 0.53), IDH2 mutational status (p = 0.35), IDH1 mutational
status (p = 0.34) and age (p = 0.08)
*The median WBC of the whole cohort was 12.7 G/L
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marked selective downregulation of NPM1 mutant
oncoprotein indicated by the appearance of active caspase-8
fragment and cleaved poly(ADP-ribose)polymerase (PARP).
Again, the combination of ATRA with ATO was even more
effective [13]. These findings were similarly reported by
others showing that ATRA and/or ATO were able to induce
proteasomal degradation of mutant NPM1 in AML cell lines
or primary samples leading to differentiation and apoptosis
[12]. Based on the in vitro data, 5 patients withNPM1-mutated
AML were treated with ATRA/ATO resulting in a transient
antileukemic effect [12]. Of note, in contrast to previous
in vitro data, Martelli et al. showed an increased sensitivity
upon treatment with ATRA/ATO 24 to 48 h before treatment
with daunorubicin [13]. These data support further exploration
of ATRA in combination with ATO and an anthracycline in
AML with mutated NPM1.
Somewhat surprisingly, the beneficial effect of ATRA in
AML with mutated NPM1 on EFS based on PP analysis did
not translate into a beneficial effect on OS. Rather both sub-
populations, NPM1-wildtype and NPM1-mutated AML, con-
tributed to the significantly improved OS (p = 0.03) in PP
analyses (Fig. 3). As there was no significant impact of
ATRA on EFS and RFS, this observation prompted us to
analyze outcome after relapse. Most patients received alloge-
neic HCT after relapse, 76 % in the ELN favorable-risk group
and 53 % in the other ELN risk groups. There was a major
beneficial effect of ATRA analyzed on an ITT and a PP basis
in the ELN favorable-risk group with a significantly better OS
after relapse in those patients randomized to and treated with
ATRA, whereas no effect was seen in the other ELN risk
groups (Fig. 3, Fig. 4). As no significant difference in the
second CR rates were evident and most patients received an
allogeneic HCT after relapse, the effect of ATRA on outcome
after relapse may be explained by preventing further relapses.
One hypothesis could be that ATRA modulates antigen pre-
sentation in the context of mucosal immunity [39] in patients
undergoing allogeneic HCT.
In conclusion, ATRA in combination with intensive induc-
tion and consolidation therapy as used in our study can be
safely administered. In ITT analysis, no impact on outcome
was demonstrated except for a beneficial effect of ATRA in
ELN favorable-risk patients. In contrast, in PP analysis,
ATRAwas associatedwith an improved EFS inNPM1-mutated
AML as well as OS in all patients. In addition, ATRA given
during first CR impacted on survival in patients with ELN
favorable-risk receiving allogeneic HCT after relapse.
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